Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer
Notice bibliographique
Résumé
Plain Language SummaryWhat is this summary about?There are few treatment choices for people with non-small cell lung cancer (NSCLC) when it gets worse after prior treatments. Available treatments lead to poor survival outcomes and severe side effects.This summarizes the results of a study called EVOKE-01. This study compared a newer medicine called sacituzumab govitecan (brand name: TRODELVY®) with a commonly used chemotherapy called docetaxel. People in the study had NSCLC that was advanced or had become metastatic after being treated with other medicines that contain platinum plus an immunotherapy.What were the results?After a median of 13 months of observation in the study, people with advanced or metastatic NSCLC who were treated with sacituzumab govitecan did not live significantly longer than those who were treated with docetaxel. However, similar to docetaxel, many people were helped by sacituzumab govitecan treatment, and patients taking sacituzumab govitecan appeared to live somewhat longer than those who were given docetaxel.People were helped no matter what type of NSCLC they had. The positive effects of sacituzumab govitecan treatment were more obvious in people whose disease did not get better after their last immunotherapy. People given sacituzumab govitecan had fewer severe side effects. Fewer had to stop sacituzumab govitecan treatment, compared with those who were given docetaxel. People who got sacituzumab govitecan in this study had similar side effects as people who took sacituzumab govitecan in other studies. Shortness of breath is a key symptom of NSCLC. People who got sacituzumab govitecan took longer to have shortness of breath compared with people who got docetaxel. This suggests that sacituzumab govitecan controlled the disease better than docetaxel.What do the results mean?This study suggested that some people with advanced or metastatic NSCLC might live slightly longer when treated with sacituzumab govitecan than with docetaxel, especially those whose cancer did not respond to earlier treatment with immunotherapy. In this study, about the same number of people who got sacituzumab govitecan or docetaxel had any side effects. Fewer people had severe/life-threatening side effects or had to stop treatment because of side effects with sacituzumab govitecan than docetaxel. These results support future studies of sacituzumab govitecan as a potential treatment for people with previously treated advanced or metastatic NSCLC.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».